Get Expert Advice for controlling your Severe Allergies

Hydroxyzine Tablets

Pronunciation

Generic Name: hydroxyzine hydrochloride
Dosage Form: tablet

Rx only

Hydroxyzine Tablets Description


Hydroxyzine hydrochloride, USP has the chemical name of (±)-2-[2-[4-(p-Chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride.



Molecular Formula: C21H27ClN2O2 · 2HCl Molecular Weight:  447.83

Hydroxyzine hydrochloride, USP occurs as a white, odorless powder which is very soluble in water.

Each tablet for oral administration contains 10 mg, 25 mg or 50 mg hydroxyzine hydrochloride, USP. Inactive ingredients include anhydrous lactose, colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate and titanium dioxide.

Hydroxyzine Tablets - Clinical Pharmacology


Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system.

Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated.

Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine’s clinical effects are usually noted within 15 to 30 minutes after oral administration.

Slideshow: 2014 Update - First Time Brand-to-Generic Switches

Indications and Usage for Hydroxyzine Tablets


For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.

Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus.

As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.

The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

Contraindications


Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride.

Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.

Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

Warnings


Nursing Mothers

It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

Precautions


THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.

Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydroxyzine. Patients should also be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased.

Geriatric Use


A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

The extent of renal excretion of hydroxyzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.

Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.

Adverse Reactions


Skin and Appendages: Oral hydroxyzine hydrochloride is associated with fixed drug eruptions in postmarketing reports.

Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature.

Anticholinergic: Dry mouth.

Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.

In post-marketing experience, the following additional undesirable effects have been reported:



Body as a Whole: Allergic reaction.

Nervous System: Headache.

Psychiatric: Hallucination.

Skin and Appendages: Pruritus, rash, urticaria.

Overdosage


The most common manifestation of hydroxyzine overdosage is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol. Do not use epinephrine as hydroxyzine counteracts its pressor action.

There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

Hydroxyzine Tablets Dosage and Administration


For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: adults, 50 to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses.

For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg for adults and 0.6 mg/kg of body weight in children.

When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.

As with all potent medication, the dosage should be adjusted according to the patient’s response to therapy.

How is Hydroxyzine Tablets Supplied

Hydroxyzine Hydrochloride Tablets, USP are available as follows:

10 mg tablets: round, film coated white tablets. Debossed HP on one side and 500 on the reverse side. They are available as follows:

Bottles of 100: NDC 23155-500-01

Bottles of 500: NDC 23155-500-05

Bottles of 1000: NDC 23155-500-10

25 mg tablets: round, film coated white tablets. Debossed HP over 501 on one side and plain on the reverse side. They are available as follows:

Bottles of 100: NDC 23155-501-01

Bottles of 500: NDC 23155-501-05

Bottles of 1000: NDC 23155-501-10

50 mg tablets: round, film coated white tablets. Debossed HP over 502 on one side and plain on the reverse side. They are available as follows:

Bottles of 100: NDC 23155-502-01

Bottles of 500: NDC 23155-502-05

Bottles of 1000: NDC 23155-502-10

Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured for:
Heritage Pharmaceuticals Inc.
Eatontown, NJ 07724
1.866.901.DRUG (3784)




51U000000193US01

Revised: 08/2014

PACKAGE LABEL PRINCIPAL DISPLAY PANEL - 10 MG(100 TABLETS)


HydrOXYzine  Hydrochloride Tablets, USP
10 mg
Rx Only
NDC 23155-500-01
100 TABLETS
EACH TABLET CONTAINS:
hydroxyzine hydrochloride, USP 10 mg
Usual Dosage: See package insert for full prescribing information.
Store at 20° to 25°C (68° to 77°F) [See USP controlled Room Temperature].
Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).
KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.
Manufactured for:
Heritage Pharmaceuticals Inc.
Eatontown, NJ 07724
1.866.901.DRUG (3784)
51U000000184US01
Revised: 08/2014

PACKAGE LABEL PRINCIPAL DISPLAY PANEL - 25 MG(100 TABLETS)


HydrOXYzine  Hydrochloride Tablets, USP
25 mg
Rx Only
NDC 23155-501-01
100 Tablets
EACH TABLET CONTAINS:
hydroxyzine hydrochloride, USP 25 mg
Usual Dosage: See package insert for full prescribing information.
Store at 20° to 25°C (68° to 77°F) [See USP controlled Room Temperature].
Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).
KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.
Manufactured for:
Heritage Pharmaceuticals Inc.
Eatontown, NJ 07724
1.866.901.DRUG (3784) 
51U000000187US01
Revised: 08/2014

PACKAGE LABEL PRINCIPAL DISPLAY PANEL - 50 MG(100 TABLETS)


HydrOXYzine  Hydrochloride Tablets, USP
50 mg
Rx Only
NDC 23155-502-01
100 Tablets
EACH TABLET CONTAINS:
hydroxyzine hydrochloride, USP 50 mg
Usual Dosage: See package insert for full prescribing information.
Store at 20° to 25°C (68° to 77°F) [See USP controlled Room Temperature].
Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).
KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.
Manufactured for:
Heritage Pharmaceuticals Inc.
Eatontown, NJ 07724
1.866.901.DRUG (3784)
51U000000190US01
Revised: 08/2014

HYDROXYZINE HYDROCHLORIDE 
hydroxyzine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:23155-500
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HYDROXYZINE HYDROCHLORIDE (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 10 mg
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS LACTOSE  
SILICON DIOXIDE  
CROSPOVIDONE  
HYPROMELLOSES  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
POLYETHYLENE GLYCOLS  
POLYSORBATE 80  
TITANIUM DIOXIDE  
Product Characteristics
Color WHITE Score no score
Shape ROUND Size 7mm
Flavor Imprint Code HP;500
Contains         
Packaging
# Item Code Package Description
1 NDC:23155-500-01 100 TABLET in 1 BOTTLE
2 NDC:23155-500-05 500 TABLET in 1 BOTTLE
3 NDC:23155-500-10 1000 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA204279 03/24/2012
HYDROXYZINE HYDROCHLORIDE 
hydroxyzine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:23155-501
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HYDROXYZINE HYDROCHLORIDE (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 25 mg
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS LACTOSE  
SILICON DIOXIDE  
CROSPOVIDONE  
HYPROMELLOSES  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
POLYETHYLENE GLYCOLS  
POLYSORBATE 80  
TITANIUM DIOXIDE  
Product Characteristics
Color WHITE Score no score
Shape ROUND Size 7mm
Flavor Imprint Code HP;501
Contains         
Packaging
# Item Code Package Description
1 NDC:23155-501-01 100 TABLET in 1 BOTTLE
2 NDC:23155-501-05 500 TABLET in 1 BOTTLE
3 NDC:23155-501-10 1000 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA204279 03/24/2012
HYDROXYZINE HYDROCHLORIDE 
hydroxyzine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:23155-502
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HYDROXYZINE HYDROCHLORIDE (HYDROXYZINE) HYDROXYZINE HYDROCHLORIDE 50 mg
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS LACTOSE  
SILICON DIOXIDE  
CROSPOVIDONE  
HYPROMELLOSES  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
POLYETHYLENE GLYCOLS  
POLYSORBATE 80  
TITANIUM DIOXIDE  
Product Characteristics
Color WHITE Score no score
Shape ROUND Size 9mm
Flavor Imprint Code HP;502
Contains         
Packaging
# Item Code Package Description
1 NDC:23155-502-01 100 TABLET in 1 BOTTLE
2 NDC:23155-502-05 500 TABLET in 1 BOTTLE
3 NDC:23155-502-10 1000 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA204279 03/24/2012
Labeler - Heritage Pharmaceuticals Inc. (780779901)
Registrant - Emcure Pharmaceuticals USA Inc. (189630168)
Establishment
Name Address ID/FEI Operations
Emcure Pharmaceuticals USA Inc. 189630168 ANALYSIS(23155-500, 23155-501, 23155-502), LABEL(23155-500, 23155-501, 23155-502), MANUFACTURE(23155-500, 23155-501, 23155-502), PACK(23155-500, 23155-501, 23155-502)
Revised: 09/2014
 
Heritage Pharmaceuticals Inc.
Hide
(web5)